A
0.136
-0.01 (-9.67%)
| Penutupan Terdahulu | 0.150 |
| Buka | 0.142 |
| Jumlah Dagangan | 56,824,261 |
| Purata Dagangan (3B) | 73,990,428 |
| Modal Pasaran | 35,914,492 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 12 Nov 2025 |
| Margin Keuntungan | -38.91% |
| Margin Operasi (TTM) | -604.96% |
| EPS Cair (TTM) | -0.300 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 28.30% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 626.29% |
| Nisbah Semasa (MRQ) | 2.02 |
| Aliran Tunai Operasi (OCF TTM) | -107.85 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -30.50 M |
| Pulangan Atas Aset (ROA TTM) | -14.19% |
| Pulangan Atas Ekuiti (ROE TTM) | -275.74% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Adaptimmune Therapeutics plc | Bercampur | Bercampur |
AISkor Stockmoo
| Nilai 35% | -3.1 |
| AI Insight info | NA |
| Penilaian Relatif info | NA |
| Kesihatan Kewangan info | -3.1 |
| Masa 35% | 1.0 |
| AI Technical info | NA |
| Osilator Teknikal info | 0.0 |
| Purata Bergerak Teknikal info | 2.5 |
| Wang Pintar 30% | 0.0 |
| Konsensus Penganalisis info | 0.0 |
| Aktiviti Orang Dalam info | NA |
| Persekitaran | ×1.21 |
| Persekitaran Makro info | -3.3 |
| Sektor berbanding Pasaran (6B) | -17.9% |
| Persetujuan Tonggak | ×1.01 |
| Tidak dikira dalam skor | |
| Volatiliti Harga info | -0.5 |
| Skor Akhir | -0.90 |
|
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 0.63% |
| % Dimiliki oleh Institusi | 44.16% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |